1. Hansch C, Smith N, Engle R, Wood H (1972) Quantitative structure-activity relationships of antineoplastic drugs: nitrosoureas and triazene-imidazoles. Cancer Che-mother Rep 56: 443–456
2. Khayat D, Lokiec F, Bizzari JP, Weil M, Meeus L, Sellami M, Rouesse J, Banzet P, Jacquillat C (1987) Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Research 47: 6782–6785
3. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ, Bugat R, Montcuquet P, Cupissol D, Lauvin R, Vilmer C, Prache C, Bizzari JP (1990) Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66 P (9): 1873–1878
4. Avril MF, Bonneterre J, Cupissol D, Grob JJ, Kalis B, Fumoleau P, Kerbrat P, Israel L, Fargeot P, Lambert D, Delaunay M, Dreno B, Vilmer C, Bizzari JP, Cour v (1991) Fotemustine and dacarbazine (DTIC): a combined regimen for malignant melanoma — Final report on 103 evaluable patients. American Society for Clinical Oncology, Houston, 17–21 mai
5. Frenay M, Giroux B, Khoury S, Derlon JM, Namer M (1991) Phase II study of a new nitrosourea, fotemustine, in recurrent supratentorial malignant gliomas. Eur J Cancer (in press)